Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

15.49USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$15.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,388
52-wk High
$16.91
52-wk Low
$2.77

Latest Key Developments (Source: Significant Developments)

GTX reports qtrly ‍loss per share $0.53​
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Gtx Inc ::GTX provides corporate update and reports third quarter 2017 financial results.GTX Inc qtrly ‍loss per share $0.53​.  Full Article

GTX Inc files for offering of up to 8.8 million shares of common stock
Friday, 20 Oct 2017 04:50pm EDT 

Oct 20 (Reuters) - GTX Inc ::GTX Inc files for offering of up to 8.8 million shares of common stock by the selling stockholders .  Full Article

Amzak Health Investors Llc reports 6.15 pct passive stake in GTX as of Sept 29
Tuesday, 10 Oct 2017 04:42pm EDT 

Oct 10 (Reuters) - GTX Inc :Amzak Health Investors Llc reports 6.15 percent passive stake in GTX Inc as of September 29 - SEC Filing‍​.  Full Article

Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29
Thursday, 5 Oct 2017 04:13pm EDT 

Oct 5 (Reuters) - GTX Inc :Aisling Capital IV LP reports 6.2 percent passive stake in GTX Inc as of Sept 29 - SEC Filing.  Full Article

GTx announces $48.5 million private placement
Tuesday, 26 Sep 2017 07:30am EDT 

Sept 26 (Reuters) - Gtx Inc :GTx announces $48.5 million private placement.GTx - ‍entered into agreement for sale of its common stock & warrants to purchase common stock in private placement with gross proceeds of $48.5 million.GTx -under terms of agreement, at close of placement, co will issue, sell 5.5 million shares to purchase up to 3.3 million additional shares of common stock.GTx Inc - co ‍to purchase up to 3.3 million additional shares of common stock at a per unit purchase price of $8.845​.  Full Article

GTx announces positive results from enobosarm Phase 2 proof-of-concept clinical trial
Wednesday, 13 Sep 2017 07:00am EDT 

Sept 13 (Reuters) - Gtx Inc :GTx announces positive results from enobosarm phase 2 proof-of-concept clinical trial in women with stress urinary incontinence.GTx Inc - ‍clinically significant reductions in incontinence episodes per day in all patients completing 12 week treatment​.GTx Inc - ‍reductions in incontinence episodes were sustained for up to 7 months following completion of enobosarm treatment​.GTx Inc - ‍mean stress leaks decreased by 83 percent from baseline over 12 weeks in study​.GTx Inc - ‍at all evaluated dose levels, enobosarm was observed to be generally safe and well tolerated​.  Full Article

GTx Q2 loss per share $0.40
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Gtx Inc :Gtx provides corporate update and reports second quarter 2017 financial results.Gtx inc qtrly loss per share $0.40.  Full Article

GTX announces positive preliminary results from ongoing trial in women with stress urinary incontinence
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Gtx Inc :GTX announces positive preliminary results from ongoing phase 2 proof-of-concept clinical trial in women with stress urinary incontinence.Reported adverse events in study are minimal with none above grade I.  Full Article

GTX reports Q1 net loss per share of $0.39
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - GTX Inc :GTX provides corporate update and reports first quarter 2017 financial results.Qtrly net loss per share $0.39.GTX Inc- expects to report topline results from its phase 2 clinical trial of enobosarm to treat stress urinary incontinence in Q3 of 2017.As of March 31, 2017, cash and short-term investments were $16.5 million compared to $21.9 million at December 31, 2016.Research and development expenses for quarter ended March 31, 2017 were $4.2 million compared to $4.0 million for same period of 2016.  Full Article

Gtx Inc qtrly loss per share $0.44
Wednesday, 15 Mar 2017 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports fourth quarter and year-end 2016 financial results . Gtx inc -expects to report preliminary results from its phase 2 clinical trial of enobosarm to treat stress urinary incontinence (sui) in q3 of 2017 . Gtx -xpects to begin an initial clinical study of selective androgen receptor degrader in men with castration-resistant prostate cancer in second half of 2017 . Gtx inc- as of december 31, 2016, cash and short-term investments were $21.9 million compared to $29.3 million at december 31, 2015 .Gtx inc qtrly loss per share $0.44.  Full Article

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage: